The Consumer Advisor

As of 2025, the Bitcoin ETF landscape is dominated by a mix of spot Bitcoin ETFs offering direct exposure to the cryptocurrency and Bitcoin futures strategy ETFs that provide exposure through futures contracts. The top Bitcoin ETFs expected to dominate based on holdings and fees reflect a balance between large assets under management (AUM), competitive expense ratios, and investor preferences for spot versus futures exposure. What Is a Spot Bitcoin ETF? Spot Bitcoin ETFs, which first began trading on U.S. exchanges Jan. 11, 2024, are exchange-traded funds that track the price of Bitcoin by directly holding the cryptocurrency itself, unlike the futures-based Bitcoin ETFs that have traded on exchanges since 2021. When an investor buys shares of a spot Bitcoin ETF, they are buying a portion of the Bitcoin held by the fund. Thus, a spot Bitcoin fund works in a similar way as a physically backed gold ETF . How to Choose the Best Spot Bitcoin ETF  Choosing the...

Here are the top 10 ETF picks for August 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management. Current market conditions and upcoming events like the U.S. Federal Reserve’s September meeting make August a timely opportunity to reallocate or accumulate: 1. SPDR S&P 500 ETF Trust (SPY) or Vanguard S&P 500 ETF (VOO) Broad U.S. equity exposure; strong performers with SPY up 8.9% YTD and focused on the AI rally and potential post-rate-cut growth ( 1 ,  2 ). Would buy: Yes, for long-term core holding and growth. 2. iShares Core S&P 500 ETF (IVV) Similar to SPY/VOO, highly liquid, low expense ratio. Would buy: Yes, for passive U.S. equity exposure ( 2 ). 3. Mirae Asset Defence Tech ETF or MarketVector Global Defense Industry ETF Defense sector ETFs are up 45%...

Nvidia’s (NASDAQ: NVDA) stock price has taken a hit, retreating from its recent high above $180. However, artificial intelligence (AI) tools are projecting that the equity will likely reclaim this level by the end of August 2025. Notably, Nvidia was among the stocks affected by Friday’s market rout , triggered by new U.S. trade tariffs and disappointing July jobs data. NVDA closed the last session down 2.3%, trading at $173. Year to date, Nvidia is still up over 25%. NVDA stock price prediction  To estimate where Nvidia stock might head by the end of August,  Finbold’s AI price prediction tool  leveraged machine learning models,  GPT-4o , Claude 3.5 Sonnet, and Grok 2 Vision, alongside a suite of technical indicators, including Moving average convergence/divergence ( MACD ), Relative Strenghth Index ( RSI ), stochastic oscillators, and 50-day moving averages (MA). According to the tool’s output, Nvidia’s share price could reach $183.17 by August 31, 2025, signaling ...

Merck, Roche and Celgene (now part of Bristol-Myers Squibb) have remained prominent players, but the market dynamics have shifted significantly in recent years. Aug 1, 2025 Update:  @POTUS  sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). Look at 2017. The trio of drugmakers together held a 45.8% share of the market, with longtime cancer leader Roche controlling 26.4% all on its own. In 2024, though, market intelligence firm EvaluatePharma expects to see much more parity. The top three’s share will shrink to 26.2%, with Roche’s dropping all the way down to 11.9%. And the No. 2 through No. 5 companies—BMS, Johnson & Johnson, Pfizer, AstraZeneca and Merck—will boas...